Skip to content
2000
Volume 21, Issue 2
  • ISSN: 1573-4080
  • E-ISSN: 1875-6662

Abstract

Diabetes mellitus continues to be a major health concern worldwide, contributing significantly to annual mortality and morbidity. Among all types of diabetes mellitus, type 2 diabetes mellitus is a pervasive health condition that affects people worldwide. Recently, various classes of drugs have been proposed for the management of T2DM. Dipeptidyl peptidase-4 inhibitors or gliptins are a class of oral medications for T2DM that target the incretin hormones GLP-1 and GIP. By increasing insulin production and decreasing glucagon release, DPP-4 inhibitors maintain glucose homeostasis. DPP-4 inhibitors provide a number of advantages over conventional antidiabetic medications, including a reduced risk of hypoglycaemic episodes, an extensive safety profile, and no weight gain. Consequently, gliptins have been a focus of study. This paper provides an overview of diabetes mellitus, focusing on its types, prevalence, and therapeutic approaches, particularly in the context of type 2 diabetes mellitus (T2DM). The synthesis of key DPP-4 inhibitors, including sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin is discussed, showcasing various synthetic strategies employed by different researchers to produce these drugs.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cei/10.2174/0115734080339904250219061503
2025-02-27
2025-09-13

  • From This Site

    /content/journals/cei/10.2174/0115734080339904250219061503
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ChawlaG. PradhanT. GuptaO. An insight into the combat strategies for the treatment of type 2 diabetes mellitus.Mini Rev. Med. Chem.202424440343010.2174/1389557523666230517113936 37198989
     [Google Scholar]
  2. RahmanM.S. HossainK.S. DasS. Role of insulin in health and disease: An update.Int. J. Mol. Sci.20212212640310.3390/ijms22126403 34203830
     [Google Scholar]
  3. AlamS. HasanM.K. NeazS. HussainN. HossainM.F. RahmanT. Diabetes mellitus: Insights from epidemiology, biochemistry, risk factors, diagnosis, complications and comprehensive management.Diabetology202122365010.3390/diabetology2020004
     [Google Scholar]
  4. KumarA. MazumderR. RaniA. PandeyP. KhuranaN. Novel approaches for the management of type 2 diabetes mellitus: An update.Curr. Diabetes Rev.2024204e05102322176810.2174/0115733998261903230921102620 37888820
     [Google Scholar]
  5. FerreiraM.K.L. Sweet tears and bitter pills: The politics of health among the Yuroks of Northern California. University of California: Berkeley with the University of California, San Francisco ProQuest Dissertations & Thesis19969723498
     [Google Scholar]
  6. KatsarouA. GudbjörnsdottirS. RawshaniA. Type 1 diabetes mellitus.Nat. Rev. Dis. Primers2017311701610.1038/nrdp.2017.16 28358037
     [Google Scholar]
  7. GollapalliM. AlansariA. AlkhorasaniH. A novel stacking ensemble for detecting three types of diabetes mellitus using a Saudi Arabian dataset: Pre-diabetes, T1DM, and T2DM.Comput. Biol. Med.202214710575710.1016/j.compbiomed.2022.105757 35777087
     [Google Scholar]
  8. NaiduS. Late stage complications of diabetes and insulin resistance.J. Diabetes Metab.201129100016710.4172/2155‑6156.1000167
     [Google Scholar]
  9. RachdaouiN. Insulin: The friend and the foe in the development of type 2 diabetes mellitus.Int. J. Mol. Sci.2020215177010.3390/ijms21051770 32150819
     [Google Scholar]
  10. FaselisC. KatsimardouA. ImprialosK. DeligkarisP. KallistratosM. DimitriadisK. Microvascular complications of type 2 diabetes mellitus.Curr. Vasc. Pharmacol.202018211712410.2174/1570161117666190502103733 31057114
     [Google Scholar]
  11. PoirierC. DesgagnéV. GuérinR. BouchardL. MicroRNAs in pregnancy and gestational diabetes mellitus: Emerging role in maternal metabolic regulation.Curr. Diab. Rep.20171753510.1007/s11892‑017‑0856‑5 28378294
     [Google Scholar]
  12. FlorentinM. KostapanosM.S. PapazafiropoulouA.K. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment.World J. Diabetes2022132859610.4239/wjd.v13.i2.85 35211246
     [Google Scholar]
  13. WuY. DingY. TanakaY. ZhangW. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.Int. J. Med. Sci.201411111185120010.7150/ijms.10001 25249787
     [Google Scholar]
  14. PrajapatiA. RanaD. RangraS. JindalA.B. BenivalD. Current status of therapeutic peptides for the management of diabetes mellitus.Int. J. Pept. Res. Ther.20243021310.1007/s10989‑024‑10590‑1
     [Google Scholar]
  15. HuysmanF. MathieuC. Diabetes and peripheral vascular disease.Acta Chir. Belg.2009109558759410.1080/00015458.2009.11680493 19994800
     [Google Scholar]
  16. SagandiraC.R. KhasipoA.Z. SagandiraM.B. WattsP. An overview of the synthetic routes to essential oral anti-diabetes drugs.Tetrahedron20219613237810.1016/j.tet.2021.132378
     [Google Scholar]
  17. KumarA. GangwarR. ZargarA.A. KumarR. SharmaA. Prevalence of diabetes in india: A review of idf diabetes atlas.Curr. Diab. Rev.202420110511410.2174/1573399819666230413094200
     [Google Scholar]
  18. SunH. SaeediP. KarurangaS. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.Diabetes Res. Clin. Pract.202218310911910.1016/j.diabres.2021.109119 34879977
     [Google Scholar]
  19. SainiK. SharmaS. KhanY. DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature.Front. Mol. Biosci.202310113062510.3389/fmolb.2023.1130625 37287751
     [Google Scholar]
  20. SeinoS. ZhangC.L. ShibasakiT. Sulfonylurea action re‐revisited.J. Diabetes Investig.201011-2373910.1111/j.2040‑1124.2010.00014.x 24843406
     [Google Scholar]
  21. WangG.S. HoyteC. Review of biguanide (metformin) toxicity.J. Intensive Care Med.20193411-1286387610.1177/0885066618793385 30126348
     [Google Scholar]
  22. SfairopoulosD. LiatisS. TigasS. LiberopoulosE. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.Hormones201817333335010.1007/s42000‑018‑0038‑0 29949126
     [Google Scholar]
  23. DeaconC.F. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.Nat. Rev. Endocrinol.2020161164265310.1038/s41574‑020‑0399‑8 32929230
     [Google Scholar]
  24. TakadaI. MakishimaM. Peroxisome proliferator-activated receptor agonists and antagonists: A patent review (2014-present).Expert Opin. Ther. Pat.20202020111310.1080/13543776.2020.1703952
     [Google Scholar]
  25. DabhiA.S. BhattN.R. ShahM.J. Voglibose: An alpha glucosidase inhibitor.J. Clin. Diagn. Res.20137123023302710.7860/JCDR/2013/6373.3838 24551718
     [Google Scholar]
  26. PeacockS.C. LovshinJ.A. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting.Can. J. Anaesth.201865214314710.1007/s12630‑017‑1019‑5 29159514
     [Google Scholar]
  27. BlickléJ.F. Meglitinide analogues: A review of clinical data focused on recent trials.Diabetes Metab.200632211312010.1016/S1262‑3636(07)70257‑4 16735959
     [Google Scholar]
  28. HaunerH. The mode of action of thiazolidinediones.Diabetes Metab. Res. Rev.200218S2Suppl. 2S10S1510.1002/dmrr.249 11921433
     [Google Scholar]
  29. PeñalverM.J.J. TimónM.I. CollantesS.C. GómezC.F.J. Update on the treatment of type 2 diabetes mellitus.World J. Diabetes201671735439510.4239/wjd.v7.i17.354 27660695
     [Google Scholar]
  30. GreenB. FlattP. BaileyC. Gliptins: DPP‐4 inhibitors to treat type 2 diabetes.Future Prescr.20078361210.1002/fps.33
     [Google Scholar]
  31. PatelB.D. GhateM.D. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors.Eur. J. Med. Chem.20147457460510.1016/j.ejmech.2013.12.038 24531198
     [Google Scholar]
  32. ThornberryN.A. GallwitzB. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).Best Pract. Res. Clin. Endocrinol. Metab.200923447948610.1016/j.beem.2009.03.004 19748065
     [Google Scholar]
  33. KushwahaR. HaqW. KattiS. Discovery of 17 gliptins in 17-years of research for the treatment of type 2 diabetes: A synthetic overview.Chem. Biol. Interact.20144137162
     [Google Scholar]
  34. GilbertM.P. PratleyR.E. GLP-1 analogs and dpp-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials.Front. Endocrinol.20201117810.3389/fendo.2020.00178 32308645
     [Google Scholar]
  35. AmbhoreJ.P. LaddhaP.R. NandedkarA. Medicinal chemistry of non-peptidomimetic dipeptidyl peptidase IV (DPP IV) inhibitors for treatment of Type-2 diabetes mellitus: Insights on recent development.J. Mol. Struct.2023128413524910.1016/j.molstruc.2023.135249
     [Google Scholar]
  36. ScheenA.J. The safety of gliptins: Updated data in 2018.Expert Opin. Drug Saf.201817438740510.1080/14740338.2018.1444027 29468916
     [Google Scholar]
  37. ScottL.J. Sitagliptin: A review in type 2 diabetes.Drugs201777220922410.1007/s40265‑016‑0686‑9 28078647
     [Google Scholar]
  38. HeY.L. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.Clin. Pharmacokinet.201251314716210.2165/11598080‑000000000‑00000 22339447
     [Google Scholar]
  39. TahraniA.A. PiyaM.K. BarnettA.H. Saxagliptin: A new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.Adv. Ther.200926324926210.1007/s12325‑009‑0014‑9 19330494
     [Google Scholar]
  40. ScottL.J. Linagliptin.Drugs201171561162410.2165/11207400‑000000000‑00000 21443284
     [Google Scholar]
  41. KeatingG.M. Alogliptin: A review of its use in patients with type 2 diabetes mellitus.Drugs201575777779610.1007/s40265‑015‑0385‑y 25855222
     [Google Scholar]
  42. TiegerE. KissV. PokolG. Studies on the crystal structure and arrangement of water in sitagliptin l -tartrate hydrates.CrystEngComm201618213819383110.1039/C6CE00322B
     [Google Scholar]
  43. GaoH. YuJ. GeC. JiangQ. Practical asymmetric synthesis of sitagliptin phosphate monohydrate.Molecules2018236144010.3390/molecules23061440 29899310
     [Google Scholar]
  44. BiftuT. FengD. QianX. (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.Bioorg. Med. Chem. Lett.2007171495210.1016/j.bmcl.2006.09.099 17055272
     [Google Scholar]
  45. HansenK.B. HsiaoY. XuF. Highly efficient asymmetric synthesis of sitagliptin.J. Am. Chem. Soc.2009131258798880410.1021/ja902462q 19507853
     [Google Scholar]
  46. BalsellsJ. HsiaoY. HansenK.B. Synthesis of Sitagliptin, the Active Ingredient in Januvia® and Janumet. Green Chem Pharm Ind.New YorkJohn Wiley & Sons, Ltd201010112610.1002/9783527629688.ch5
     [Google Scholar]
  47. RamachandraRD NarayanraoKR MarutiG AtulKS Atul, Process for the preparation of sitagliptin and intermediate compounds. WO2014023930AI,,2014
     [Google Scholar]
  48. OhD. LeeJ. YangS. Enantioselective Synthesis of (R)-Sitagliptin via Phase-Transfer Catalytic aza-Michael Addition.ACS Omega2024913153281533810.1021/acsomega.3c10080 38585066
     [Google Scholar]
  49. PolyakovaE.B. SabirzyanovD.R. ProzorovaN.A. FoteevaA.V. Physicochemical properties and methods of analysis of vildagliptin.(review) Pharm. Chem. J.202256111011710.1007/s11094‑022‑02606‑1 35370321
     [Google Scholar]
  50. RathodV. SainiP. KaurR. MarimgantiS. RanbhanK.J. A critical account of synthetic approaches toward vildagliptin, an antidiabetic drug.Org. Process Res. Dev.202327111880189910.1021/acs.oprd.3c00048
     [Google Scholar]
  51. AlcántaraC.M. AlcántaraA.R. Biocatalyzed synthesis of antidiabetic drugs: A review.Biocatal. Biotransform.2018361124610.1080/10242422.2017.1323887
     [Google Scholar]
  52. VillhauerE.B. BrinkmanJ.A. NaderiG.B. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.J. Med. Chem.200346132774278910.1021/jm030091l 12801240
     [Google Scholar]
  53. SinghS.K. ManneN. PalM. Synthesis of (S)-1-(2-chloroacetyl) pyrrolidine-2-carbonitrile: A key intermediate for dipeptidyl peptidase IV inhibitors.Beilstein J. Org. Chem.200842010.3762/bjoc.4.20 18941490
     [Google Scholar]
  54. A kind of preparation method of vildagliptin. CN105712920A,2016
     [Google Scholar]
  55. XueZK ChenSX LutaoXW Efficient synthesis of vildagliptin by Xue. CN106966947A,,2017
     [Google Scholar]
  56. HuX. LiY. ZhangL. An efficient synthesis of Vildagliptin intermediates.Indian J. Chem.20212021601128113110.56042/ijcb.v60i8.30478
     [Google Scholar]
  57. BoultonD.W. Clinical pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor.Clin. Pharmacokinet.2017561112410.1007/s40262‑016‑0421‑4 27282159
     [Google Scholar]
  58. TharejaS. AggarwalS. MallaP. HaksarD. BhardwajR.T. KumarM. Saxagliptin: A new drug for the treatment of type 2 diabetes.Mini Rev. Med. Chem.201010875976510.2174/138955710791572424 20402634
     [Google Scholar]
  59. CerneaS. CahnA. RazI. Saxagliptin for the treatment of diabetes - a focus on safety.Expert Opin. Drug Saf.201615569770710.1517/14740338.2016.1159675 26923222
     [Google Scholar]
  60. AugeriD.J. RoblJ.A. BetebennerD.A. Discovery and preclinical profile of Saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.J. Med. Chem.200548155025503710.1021/jm050261p 16033281
     [Google Scholar]
  61. SavageS.A. JonesG.S. KolotuchinS. RamrattanS.A. VuT. WaltermireR.E. Preparation of Saxagliptin, a Novel DPP-IV Inhibitor.Org. Process Res. Dev.20091361169117610.1021/op900226j
     [Google Scholar]
  62. ModyG.U. RetlichS. FriedrichC. Clinical pharmacokinetics and pharmacodynamics of linagliptin.Clin. Pharmacokinet.201251741142710.2165/11630900‑000000000‑00000 22568694
     [Google Scholar]
  63. McKeageK. Linagliptin: An update of its use in patients with type 2 diabetes mellitus.Drugs201474161927194610.1007/s40265‑014‑0308‑3 25297911
     [Google Scholar]
  64. DingH.X. LiuK.K.C. SakyaS.M. FlickA.C. O’DonnellC.J. Synthetic approaches to the 2011 new drugs.Bioorg. Med. Chem.201321112795282510.1016/j.bmc.2013.02.061 23623674
     [Google Scholar]
  65. EckhardtM. LangkopfE. MarkM. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.J. Med. Chem.200750266450645310.1021/jm701280z 18052023
     [Google Scholar]
  66. HuangY HeX WuT ZhangF Synthesis and characterization of process-related impurities of antidiabetic drug linagliptin Molecules2016218104110.3390/molecules21081041
     [Google Scholar]
  67. Divis Laboratories Limited, Divis’s approach towards Linagliptin. IN201302189,2013
  68. AgrawalR. BahareS.R. JainP. DikshitN.S. GangulyS. Novel serine protease dipeptidyl peptidase IV inhibitor: Alogliptin.Mini Rev. Med. Chem.201212131345135810.2174/138955712804586684 22512582
     [Google Scholar]
  69. TrailokyaAA ZargarAH TiwaskarM KaleS ShirsatA Commentary on cardiovascular safety of DPP4Is: Focus on Alogliptin. Indian J. Pharm and Pharmacol2023101505310.18231/j.ijpp.2023.013
  70. FengJ ZhangZ WallaceMB Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase iv. J Med Chem200851144357710.1021/jm8006799 17441705
  71. JeanneretJL Dipeptidyl peptidase IV and its inhibitors: Therapeutics for type 2 diabetes and what else? J Med Chem20145762197221210.1021/jm400658e 24099035
     [Google Scholar]
  72. HuanY JiangQ LiuJ ShenZ Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors. J Pharmacol Toxicol Methods20157181210.1016/j.vascn.2014.11.002 25464020
     [Google Scholar]
  73. VasenH.F.A. MösleinG. AlonsoA. Guidelines for the clinical management of familial adenomatous polyposis (FAP).Gut200857570471310.1136/gut.2007.136127 18194984
     [Google Scholar]
  74. MaromE. MizhiritskiiM. RubnovS. Patent and Trademark Office. Washington, DC: U.S. U.S. Patent No. 8,841,447,2014
     [Google Scholar]
  75. JiatongZ HanyueY ChaoCX D SimeiZ. Synthesis method of Alogliptin benzoate. CN104193726A,2014
     [Google Scholar]
  76. YamadaM. HiranoS. TsuruokaR. Development and scale-up of an asymmetric synthesis process for alogliptin.Org. Process Res. Dev.202125232733610.1021/acs.oprd.0c00544
     [Google Scholar]
/content/journals/cei/10.2174/0115734080339904250219061503
Loading
Synthetic Overview of FDA-Approved Dipeptidyl Peptidase-4 Inhibitors (DPP-4I)
Curr. Enzym. Inhib. 21, 116 (2025); https://doi.org/10.2174/0115734080339904250219061503
/content/journals/cei/10.2174/0115734080339904250219061503
/content/journals/cei/10.2174/0115734080339904250219061503
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): alogliptin; DPP-4 inhibitor; linagliptin; saxagliptin; sitagliptin; Type-2 diabetes mellitus; vildagliptin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test